Post Reply
4061-4080 of 10899
the market trying to adjust the news that CCP is restricting pharmas from overcharging, so as to control healthcare cost at individual level... can go take a look at india. whereby they prefer generic drugs even though it violates patent laws in the state.
BIG may plunge further depending how it intends to tackle this challenge.. note that the newspaper ST cover C&O pharmeceutical
Cannot stop people from selling cheap, right?
win_88 ( Date: 10-Mar-2010 15:38) Posted:
|
One analyst's meat is another analyst's poison. So some who wants to buy downgrades the counter and some who wants to sell upgrades it. Buy because of prospects and not because the analyst says so. My experience with analysts previously was always back-stabbed by them. So doyour own homework.
Fear that normally kills the feared.
win_88 ( Date: 10-Mar-2010 15:38) Posted:
|
y keep dropping>????
Can buy now. If not today, tomorrow will buy.
investor ( Date: 08-Mar-2010 14:11) Posted:
|
Nomura target $1.23 CS target .75.....so different in views
Credit Suisse has downgraded Biosensors to a 'hold' target price 0.75, down from previous target price of 0.90.
Reason cited was the China govt's action to regulate and bring down the price of DES, which will affect JWMS.
For info. Not a call to buy/sell.
Nomura's report is 17 pages long and gave quite a detailed picture of the global DES landscape.
They mentioned that Boston Scientific (BSX) is terminating the clinical trial using the Labcoat biodegradable polymer with their drug Paclitaxel.
Instead, they are going to initiate a clinical trial using the everolimus drug, with the biodegradable polymer. As we know, BSX licensed the sale of the Xience DES from Abbot, which is using the everolimus drug with a permanent polymer, and called it the PROMUS DES.
A little bit of history here. Originally, Biosensors sold the everolimus drug clinical trial using their biodegradable polymer to Guidant ,and Guidant in turn was bought over by BSX, which sold the DES formulation to Abbot Lab.
Guidant had use the clinical trials results to futher develope the Xience DES, BUT with a PERMANENT polymer ! (A step backwards).
Why ? - Because probably they did not want to pay royalties to Biosensors, which owns a patent covering the use of any limus drug (including Everolimus) on a stent with biodegradable polymer.
Now that BSX is initiating this trial, using Everolimus with a biodegradable polymer, Nomura highlighted that they might be liable to infringe on Biosensors' patent.
SO, it is back to square one for the Everolimus DES, and it will be interesting (exciting actually), to see if Abbot Lab will follow their licensee. BSX to also initiate a trial using a biodegradable polymer.
Also, does BSX have to continue to pay Abbot Labs, royalties when they mkt the new DES with biodegradable polymer ? Whatever, it is, it will add pressure on Abbot Lab.
So what does this mean for Biosensors ? - Major players are getting into the act on biodegradable polmyer, and Nomura has mentioned that J & J will apply for CE mark for their Nevo biodegradable polymer DES in Q1 2010. And Biosensors is clearly the leader here, with a large clinical trial (Leader's trial), that is approaching 3 years (by this sept 2010), and with quite a large number of registries numbering 1,000-5,000, initiated by Terumo and Biosensors.
Nomura also mentioned that Terumo is conducting a NORBORI 2 trial comparing the Biosensors' DES (the Nobori) to the Xience DES (currently the most popular DES in the mkt), and if the results are favourable, it could be a potential M & A catalyst for Terumo to acquire Biosensors.
All the above are for information only, and the various scenarios painted above may not happen. Not a call to buy/sell.
I am holding still since year 2006... ha ha... this counter really test your "endurance" level....
I am watching the game at max price of $0.69 (some averaging at 20+ cents) ..... the sucky thing is , not a single dividend ...
I just want to see if it can chiong all the way to the good old days... $1
Analyst report from Nomura 04/03/2010
Investment summary
In this note, we analyse the 4Q09 results and key developments of the global medtech players in the DES space – Johnson & Johnson (JNJ), Boston Scientific (BSX), Medtronic (MDT) and Abbott (ABT), and the post-IPO plans of Chinese DES manufacturer Lepu. We also highlight MDT’s acquisition of BioMatrix’s sole distributor in Germany, which we think raises potential downside risk to its EU market share. Net net, we believe BIG remains well-positioned within the competitive DES global landscape, notwithstanding the uncertainties in Germany. Reiterate BUY.
Potential downside risk for BIG has surfaced from MDT’s acquisition of Invatec and its affiliates Fogazzi and Krauth, the latter of which is the sole distributor of BioMatrix in Germany – one of the sizeable DES markets in the EU. While we do not see any immediate risks in the near term, we think there is a possibility that MDT may terminate third-party stent sales after the transaction closes in 2Q10F. We believe BIG could either look to establish its own sales force or re-contract another distributor in the worst-case scenario.
We believe the acquisition of Invatec, an Italy-based cardiovascular device company, establishes a key precedent transaction metric for Biosensors at 2.9-4.2x price/sales, which values a potential takeout at S$1.17-1.39/share.
In our view, BioMatrix/Nobori’s leading-edge technology will continue to enjoy a comfortable lead following BSX’s announcement that it will put on hold its Labcoat Element (a paclitaxel-eluting stent with biodegradable polymer technology acquired by BSX in January 2009) and reinitiate a biodegradable polymer stent programme using everolimus. JNJ’s NEVO will be the only remaining biodegradable polymer stent in the global product pipeline, to be filed for CE approval in 1Q10F.
BioMatrix/Nobori platform had a 5% OUSeJ market share in 4Q09 by revenue, up from 3% in 4Q08, with BioMatrix ahead with a 3% share on our estimates). Its unit share is higher at 5-7%, according to management, which we think is respectable given BIG’s limited marketing capabilities. The continued relevance of Cypher in OUSeJ (stable market share) also bodes well for BioMatrix, whose LEADERS trial data, pitted against the JNJ stent, will remain a strong marketing point, we believe.
We believe Lepu’s aggressive post-IPO expansion to establish more sales channels nationwide could accelerate the ongoing strategic discussions between Weigao and BIG on their JV, JWMS. Near-term risk is limited due to JWMS’ strong ties with Weigao, but a new product pipeline, which BIG can offer, is necessary to moderate the rate of ASP decline, in our view.
At this stage, we believe PCI volume growth potential (30% pa) in China outweighs uncertainties on stent pricing. In our opinion, more affordable pricing is a prerequisite to realising significant volume growth potential in tier 2/3 cities.
What happened to all the HEARTS?
With or withOUT SENSOR!
Welcome back and Happy New Year! Don't think there will be any significant move until after next week after China comes back from the holidays. Range bound between 0.81-0.86
allright ( Date: 18-Feb-2010 11:15) Posted:
|
Happy New Year everyone. I have been away and just came back . What's happening to this share?
last one hour large lots buying up... BB coming in again?
gbleng ( Date: 03-Feb-2010 10:51) Posted:
|
Looks like no more interest in the stock....... drifting...drifting... aimless.... until.......
looks like hard to break thru 0.9... granite ceiling...
My guess is that it will be range-bound between 0.81 - 0.86
shorted this counter today. i think it has been too high at the moment, some corrections should be on the way.
will have to cut if it break through $0.9+
any guys here think the same for this counter?
wah amazing... i morning go mtg come back then realised missed my exit sign.... sigh, gota wait long long
novicealex ( Date: 02-Feb-2010 11:06) Posted:
|